ClinicalTrials.Veeva

Menu

Activating Community Support for Substance Users

Johns Hopkins University logo

Johns Hopkins University

Status and phase

Completed
Phase 2

Conditions

Substance Use Disorders

Treatments

Behavioral: Community Support Intervention Group
Behavioral: Substance Use Disorder Educational Group

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT03194295
IRB00130614
1R34DA042320-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Efforts to improve methadone maintenance outcomes are often thwarted by strong social networks that reinforce substance use and other risk behaviors. The proposed study the feasibility and preliminary efficacy of a practical community support intervention that employs an alteration model of social network change. The intervention works with patients and at least one drug-free family or friend to support participation in community activities designed to mobilize recovery support and expand personal drug-free social networks.

Full description

Opioid-dependent individuals in methadone maintenance have high rates of illicit drug and alcohol use. The individual and public health concerns of poorly and partially treated substance use include social, medical, psychiatric, and healthcare costs. Efforts to improve outcomes are often thwarted by strong social networks that reinforce substance use and other high-risk drug use and sexual behaviors. Many urban substance users lack the financial resources to simply move away from adverse community influences. While clinical providers are well aware of the power of social network influences, existing research provides relatively little direction about how to help substance users change "people, places, and things." An under-explored strategy to achieve this desired outcome is to mobilize social support found in the personal social networks of people with substance use disorder. A considerable amount of research demonstrates that people with substance use disorder routinely have drug-free family or friends in their social networks, and that these individuals are terribly underutilized for supporting recovery efforts. Social support is reliably associated with good health behaviors and more positive and sustained substance abuse treatment outcomes. The inclusion of drug-free family and friends also provides a pathway to modify social networks by facilitating activity with other drug-free people within and outside of the patient's social network. This type of work supports an alteration model of network change. This protocol uses an alteration model to develop a promising 12-week community support intervention designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. This highly structured and manual-guided therapeutic group works with patients and at least one drug-free family member or friend (community support person -- CSP) to expand the quantity and quality of the patients' drug-free social network, and to reduce and eliminate interactions with active drug users. This outcome is achieved via a series of "homework" assignments that require the patient and CSP to participate together in two drug-free activities per week that include the presence of other drug-free individuals (e.g., Narcotics Anonymous (NA)/Alcoholics Anonymous (AA), religious activities), and to discuss their experiences within the group setting. This intervention will be compared to Standard Care that includes a substance abuse education group with weekly homework. Specific aims evaluate feasibility outcomes and the extent to which the intervention supports an alteration model. Short-term efficacy will be assessed using measures of perceived social support and network support for abstinence. Secondary outcomes will evaluate substance use and psychosocial outcomes. Data will support a larger-scale randomized clinical trial (RCT) better isolating the clinical benefits of activating existing social support and facilitating community involvement.

Enrollment

49 patients

Sex

All

Ages

21 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (for the ATS participant):

  • ATS treatment participation of more than 4-weeks
  • Submission of at least one drug-positive urine sample
  • Expressed willingness to include a drug-free support person in treatment

Exclusion Criteria (for the ATS participant):

  • Pregnancy
  • Acute medical problem that requires immediate and intense medical management (e.g., AIDS defining illness; unstable diabetes)
  • Presence of a formal thought disorder, delusions, hallucinations, or imminent risk of harm to self or others
  • Unable to read.

Exclusion Criteria (for the CSPs)

  • Submission of a drug-positive urine sample
  • Pregnancy
  • Acute medical problem that requires immediate and intense medical management (e.g., AIDS defining illness; unstable diabetes)
  • Presence of a formal thought disorder, delusions, hallucinations, or imminent risk of harm to self or others
  • Unable to read.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

49 participants in 2 patient groups

Community Support Intervention
Experimental group
Description:
Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
Treatment:
Behavioral: Community Support Intervention Group
Standard Care
Active Comparator group
Description:
Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
Treatment:
Behavioral: Substance Use Disorder Educational Group

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems